Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,102 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

NCT03539731
View directory record Official record
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 6, 2026, 2:42 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy

NCT04829461
View directory record Official record
Conditions
Cystoscopy, Ureteral Stent
Interventions
Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal, Standard of care reusable cystoscope used for stent removal
Device
Lead sponsor
Ambu Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hershey, Pennsylvania • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction

NCT04340180
View directory record Official record
Conditions
Breast Benign Tumor, Breast Malignant Tumor
Interventions
Standard of Care (SOC) gadolinium Breast MRI, reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds

NCT02465073
View directory record Official record
Conditions
Wound Infection
Interventions
NXTSC wound gel, NXTSC wound gel plus Standard of Care, Standard of Care Group
Device
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 6, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

NCT02910063
View directory record Official record
Conditions
B-Cell Non Hodgkin Lymphoma
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Duarte, California • Baltimore, Maryland • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Immunotherapy Study for Surgically Resected Pancreatic Cancer

NCT01072981
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreas Immunotherapy, Gemcitabine, 5FU Chemoradiation
Biological · Drug · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 6, 2026, 2:42 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Triggered Escalating Real-time Adherence (TERA) Intervention

NCT03292432
View directory record Official record
Conditions
HIV Infections
Interventions
TERA Intervention (TERA), Standard of Care (SOC)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 24 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Early Phase 1 Interventional

Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet

NCT05658263
View directory record Official record
Conditions
Dysbiosis, Sarcopenia, Colon Cancer
Interventions
Standard Diet, BIG MACS Diet
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

NCT07162194
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy
Procedure · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
20 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Restorative Eye Treatment and INhance in Upper Eyelid Blepharoplasty Surgery

NCT05007288
View directory record Official record
Conditions
Eyelid Dermatochalasis, Dermatochalasis
Interventions
Restorative Eye Treatment (RET) cream, INhance with Trihex Technology
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480
View directory record Official record
Conditions
Multiple Myeloma, Secondary Immunodeficiency
Interventions
IGI, 10%
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

NCT00234910
View directory record Official record
Conditions
HIV Infection
Interventions
Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2008 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Phase 1 Interventional

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

NCT07499674
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Abenacianine, Near Infrared (NIR) Imaging
Drug · Other
Lead sponsor
Vergent Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Duarte, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Terminated No phase listed Observational

Localized Alveolar Ridge Augmentation With Dental Implant

NCT00991965
View directory record Official record
Conditions
Alveolar Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 6, 2026, 2:42 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

NCT02135692
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Newport Beach, California • Riverside, California • Rolling Hills Estates, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 6, 2026, 2:42 AM EDT
Enrolling by invitation Phase 4 Interventional

Intra-Articular Catheter Total Knee Arthroplasty

NCT06580899
View directory record Official record
Conditions
Continuous Local Infiltration Analgesia, Intra-articular Catheter, Total Knee Arthroplasty
Interventions
Intra-articular catheter, Routine Standard of Care Treatment
Device · Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 6, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 6, 2026, 2:42 AM EDT